Is this email not displaying correctly?
View it in your browser.
Newswise - News for Journalists

Newswise Special Wire
Tuesday, September 8, 2015

Public edition |

Newswise Cancer Research Wire for 08-Sep-2015

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

Nature: Study Creates Cell Immunity to Parasite That Infects 50 Million

Multi-institutional, multidisciplinary study looks past antibiotics and sanitation to a third strategy to control infectious disease: Adjusting the landscape of the human body to remove the mechanism that allows pathogens to cause disease.

 • Image(s) embedded •  (Embargo expired on 08-Sep-2015 at 05:00 ET)

Nature Scientific Reports; NIH R01AI026649; NIH F32AI09304; NIH CA143971; NIH CA075115

– University of Colorado Cancer Center

Increased Detection of Low-Risk Tumors Driving Up Thyroid Cancer Rates, Mayo Study Finds

Low-risk cancers that do not have any symptoms and presumably will not cause problems in the future are responsible for the rapid increase in the number of new cases of thyroid cancer diagnosed over the past decade, according to a Mayo Clinic study published in the journal Thyroid. According to the study authors, nearly one-third of these recent cases were diagnosed when clinicians used high-tech imaging even when no symptoms of thyroid disease were present.

– Mayo Clinic

Pancreatic Cancer Subtypes Discovered in Largest Gene Expression Analysis of the Disease to-Date

The study, published in Nature Genetics, paves the way for potential personalized medicine approaches for the deadly cancer type.

Nature Genetics, Sept-2015

– University of North Carolina Health Care System

Rutgers Cancer Institute One of Few Centers on East Coast to Offer Immunotherapy Clinical Trial Targeting Leukemia/Lymphoma

Rutgers Cancer Institute of New Jersey is one of a few East Coast sites to offer a clinical trial investigating an experimental drug in the treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). REGN1979 is designed to use the body’s own defenses to fight illness by helping T cells find and destroy B cells, including those cancerous B cells found in NHL and CLL. The goal is to determine how much of the drug can be given safely to patients who have the CD20 protein on their lymphoma or CLL cells.

 • Image(s) embedded • 

– Rutgers Cancer Institute of New Jersey

Rare Melanoma Carries Unprecedented Burden of Mutations

A rare, deadly form of skin cancer known as desmoplasmic melanoma (DM) may possess the highest burden of gene mutations of any cancer, suggesting that immunotherapy may be a promising approach for treatment, according to an international team led by UC San Francisco scientists. One of these mutations, never before observed in any cancer, may shield nascent DM tumors from destruction by the immune system and allow further mutations to develop.

(Embargo expired on 07-Sep-2015 at 08:00 ET)

– University of California, San Francisco (UCSF)

Top Stories 4 Sept 2015

Click to read today's top stories.

– Newswise Trends

Drug for Fungal Infections in Lung Transplant Recipients Increases Risk for Skin Cancer, Even Death

Voriconazole, a prescription drug commonly used to treat fungal infections in lung transplant recipients, significantly increases the risk for skin cancer and even death, according to a new study by UCSF researchers.

(Embargo expired on 03-Sep-2015 at 00:00 ET)

American Journal of Transplantation

– University of California, San Francisco (UCSF)

Genetic Testing All Women for Breast Cancer Might Not Be Worth the Cost

Women who are carriers of mutated BRCA genes are known to have a significantly higher risk for developing breast and ovarian cancers than those who don’t have the mutations. But a new study by UCLA faculty questions the value of screening for the genetic mutations in the general population—including those who do not have cancer or have no family history of the disease— because of the high cost.

 • Image(s) embedded •  (Embargo expired on 03-Sep-2015 at 11:00 ET)

JAMA Oncology

– University of California, Los Angeles (UCLA), Health Sciences

The Ontario Institute for Cancer Research and the Structural Genomics Consortium Develop and Give Away New Drug-Like Molecule to Help Crowd-Source Cancer Research

Researchers from the Ontario Institute for Cancer Research (OICR) and the Structural Genomics Consortium (SGC) at the MaRS Discovery District in Toronto have developed a new drug prototype called OICR-9429 and made it freely available to the research community. Already research conducted by international groups using OICR-9429 has shown it to be effective in stopping cancer cell growth in breast cancer cell lines and a specific subtype of leukemia cells.

 • Image(s) embedded •  (Embargo expired on 03-Sep-2015 at 11:30 ET)

– Ontario Institute for Cancer Research

New Role for an Old Protein: Cancer Causer

A protein known to play a role in transporting the molecular contents of normal cells into and out of various intracellular compartments can also turn such cells cancerous by stimulating a key growth-control pathway.

(Embargo expired on 03-Sep-2015 at 14:00 ET)

Science, September 3, 2015; CA103866; AI47389; CA155169; CA092629; 1DP2CA195761-01; GM07739; PC094483

– Whitehead Institute for Biomedical Research

Venom From Wasp Could Be Used to Fight Cancer

A toxin in the sting of Polybia paulista, a wasp of Brazil, kills cancer cells without harming normal cells.

BBC News; Biophysical Journal

– Newswise

Top Stories 3 Sept 2015

Click to view today's top stories.

– Newswise Trends

Variations in Cell Programs Control Cancer and Normal Stem Cells

In the breast, cancer stem cells and normal stem cells can arise from different cell types and tap into distinct yet related stem cell programs, according to Whitehead Institute researchers. The differences between these stem cell programs may be significant enough to be exploited by future therapeutics.

Nature, Sept-2015; NRFNRFF2015-04; P01-CA080111; U01-CA184897; R01-CA078461; K99-CA194160

– Whitehead Institute for Biomedical Research

Acupuncture Dramatically Reduces Hot Flashes in Breast Cancer Survivors, Penn Study Suggests

Acupuncture may be a viable treatment for women experiencing hot flashes as a result of estrogen-targeting therapies to treat breast cancer, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

Journal of Clinical Oncology

– Perelman School of Medicine at the University of Pennsylvania

Targeting Newly Discovered Pathway Sensitizes Tumors to Radiation and Chemotherapy

In some patients, aggressive cancers can become resistant to chemotherapy and radiation treatments. In a paper published in the journal Nature Communications, University of California, San Diego School of Medicine researchers identified a pathway that causes the resistance and a new therapeutic drug that targets this pathway.

Nature Communications

– University of California, San Diego Health Sciences

Team Decodes Structure of Protein Complex Active in DNA Repair

The multifunctional ubiquitin tweaks the activity of newly made proteins, which can influence DNA damage repair via BRCA1 and anti-inflammatory responses. One enzyme in particular, BRCC36, removes a specific type of ubiquitin central to DNA damage repair and inflammation. But BRCC36 doesn’t act on its own. It’s part of a complex with KIAA0157. How these two work together is finally coming into focus.

 • Image(s) embedded • 

Molecular Cell; CA138835, CA17494, GM101149

– Perelman School of Medicine at the University of Pennsylvania

The Medical Minute: Blood in the Urine Often an Important Warning Sign

Blood in the urine can be a scary sight, yet it’s a symptom many people ignore until it is bad enough to land them in a hospital emergency department.

– Penn State Milton S. Hershey Medical Center

Free e-Book Offers Tips for Reducing Breast Cancer Risk at Nearly Any Age​​​​​​​​​​​​​

A free e-book provides practical, science-based advice for lowering breast cancer risk at every stage of life. Written for a lay audience, “Together — Every Woman’s Guide to Preventing Breast Cancer” aims to help women improve their breast health and the breast health of their loved ones.

 • Image(s) embedded • 

– Washington University in St. Louis

Cellular Recycling Complexes May Hold Key to Chemotherapy Resistance

Upsetting the balance between protein synthesis, misfolding, and degradation drives cancer and neurodegeneration. Recent cancer treatments take advantage of this knowledge with a class of drugs that block protein degradation, known as proteasome inhibitors. Widespread resistance to these drugs limits their success, but Whitehead researchers have discovered a potential Achilles heel in resistance. With such understandings researchers may be able to target malignancy broadly, and more effectively.

(Embargo expired on 02-Sep-2015 at 00:00 ET)

eLife; ALTF 739-2011; K08NS064168

– Whitehead Institute for Biomedical Research

Telomerase Targeting Drug Demonstrates Benefit in Myelofibrosis Treatment

Imetelstat, a novel drug that targets telomerase, has demonstrated potential value in treating patients with myelofibrosis, according to the results of a study published today in the New England Journal of Medicine.

(Embargo expired on 02-Sep-2015 at 17:05 ET)

New England Journal of Medicine

– Mayo Clinic

Top Stories 2 Sept 2015

Click to see today's top stories.

– Newswise Trends

Columbia Engineering Team Develops Targeted Drug Delivery to Lung

Researchers from Columbia Engineering and Columbia University Medical Center have developed a new method that can target delivery of very small volumes of drugs into the lung. Their approach, in which micro-liters of liquid containing a drug are instilled into the lung, distributed as a thin film in the predetermined region of the lung airway, and absorbed locally, may provide much more effective treatment of lung disease. (August 31 online Early Edition PNAS)

 • Image(s) embedded • 

PNAS, Aug 31 2015

– Columbia University School of Engineering and Applied Science

Mutated Tumor Suppressor Uses Epigenetics to Drive Aggressive Cancers

Aggressive cancer growth and alterations in gene activity without changes in DNA sequence (epigenetics) are associated with mutant p53 proteins, which has implications for such difficult-to-treat cancers as those in the pancreas and breast.

Nature; R01 CA 78831

– Perelman School of Medicine at the University of Pennsylvania

Scientists Discover Mechanism for Air Pollution-Induced Liver Disease

A research team led by Kezhong Zhang, Ph.D., at the Wayne State University School of Medicine’s Center for Molecular Medicine and Genetics, has discovered that exposure to air pollution has a direct adverse health effect on the liver and causes liver fibrosis, an illness associated with metabolic disease and liver cancer.

 • Image(s) embedded • 

Journal of Hepatology, online July 26, 2015

– Wayne State University Division of Research

International Experts Talk Cancer, Sickle Cell, Diabetic Nephropathy Therapies at Endothelin Meeting in Savannah

Endothelin (ET) plays a role in many functions throughout the body, including blood vessel constriction and blood pressure regulation, and insights gained through the study of ET have great therapeutic potential for health and disease. As ET experts convene for the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics, the translational aspect of ET research will take center stage during the “Endothelin Therapeutics—Where Are We?” symposium.

Endothelin 14 Conference

– American Physiological Society (APS)

New York Times Well Columnist and Cancer Survivor Suleika Jaouad to Open AACI/CCAF Annual Meeting

New York Times Well Columnist Suleika Jaouad will make keynote presentation at the annual meeting of the Association of American Cancer Institutes, October 25; PBS NewsHour analyst Susan Dentzer will be the moderator.

 • Image(s) embedded • 

– Association of American Cancer Institutes (AACI)

Statistical Model May Identify Patients Most Likely to Benefit from Surgery for Mesothelioma

A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma

(Embargo expired on 01-Sep-2015 at 01:05 ET)

Ann Thorac Surg 2015;100:890–7

– Society of Thoracic Surgeons

Genetic Landscape Can Impact Treatment for Children with Rare, Aggressive Cancer

For children with rare, aggressive and advanced cancer, precision medicine may help doctors determine their best treatment options, a new study finds. Using information from a patient’s entire genome helped suggest personalized treatment options for nearly half of children with cancer, and led to specific treatment changes in a quarter of these patients.

 • Video / Image(s) embedded •  (Embargo expired on 01-Sep-2015 at 11:00 ET)

Journal of the American Medical Association; 1UM1HG006508

– University of Michigan Health System

Incorporating Genomic Sequencing, Counseling into Pediatric Cancer Treatment Shows Benefit

In a study that included children and young adults with relapsed or refractory cancer, incorporation of integrative clinical genomic sequencing data into clinical management was feasible, revealed potentially actionable findings in nearly half of the patients, and was associated with change in treatment and family genetics counseling for a small proportion of patients, according to a study in the September 1 issue of JAMA.

(Embargo expired on 01-Sep-2015 at 11:00 ET)


– JAMA - Journal of the American Medical Association

UCLA Researchers Develop a Likely New Combo Treatment for the Deadliest Form of Brain Cancer

UCLA scientists have developed a potentially promising new combination therapy for glioblastoma, the deadliest form of brain cancer.

 • Image(s) embedded • 


– University of California, Los Angeles (UCLA), Health Sciences

Top Stories 1 September 2015

Click to see today's top stories.

– Newswise Trends

Study Shows K17 Protein Promotes Cancer

Keratin 17 (K17), a protein previously believed to provide only mechanical support for cancer cells, appears to play a crucial role in degrading a key tumor suppressor protein in cancer cells named p27. This finding, published in the September 1 issue of Cancer Research, is based on the work of researchers in the Department of Pathology at Stony Brook University School of Medicine. They found that K17 has the ability to enter the nucleus of cancer cells, leading to the degradation of p27. The work illustrates for the first time that a keratin can function to promote the development of cancer. Furthermore, the paper details that tumors with high levels of K17 are biologically more aggressive and have a worse prognosis than low K17 tumors.

 • Image(s) embedded • 

Cancer Research

– Stony Brook University

Georgetown Lombardi Offers New Melanoma Study Comparing Two Treatment Regimens

A new nationwide clinical trial comparing two groups of drugs — both effective in treating melanoma.

– Georgetown Lombardi Comprehensive Cancer Center

September is Prostate Cancer Awareness Month

Prostate cancer is the second leading cause of cancer death in American men. One in seven men will be diagnosed with prostate cancer and 233,000 new cases are diagnosed annually. That said, not every diagnosis warrants intervention. Mount experts are using a powerful new technique, MRI Fusion Biopsy, to more accurately diagnose both small and large cancer lesions, treating only the affected areas and monitoring areas that don’t require immediate intervention. Experts are available to comment on this important discussion in the field, and to share tips on prevention.

Expert(s) available

– Mount Sinai Medical Center

September is Thyroid Cancer Awareness Month

According to the American Cancer Society, 62,000 Americans will be diagnosed with thyroid cancer in 2015, most of them before reaching age 55. Experts at the Head and Neck Institute at Mount Sinai Health System encourage the public to perform regular thyroid neck self-exams and be aware of the symptoms of thyroid cancer.

Expert(s) available

– Mount Sinai Medical Center

Inducing Metabolic Catastrophe in Cancer Cells

Researchers at Harvard Medical School describe a way to force cancer cells to destroy a key metabolic enzyme they need to survive.

 • Image(s) embedded •  (Embargo expired on 31-Aug-2015 at 09:00 ET)

The Journal of Cell Biology; HHSN268201000035C; R01 MH067880; 8P41GM103533-17

– The Rockefeller University Press

Men With Low-Risk Prostate Cancer in Active Surveillance Program Not Likely to Succumb to the Disease, Study Shows

Men with relatively unaggressive prostate tumors and whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to results of a study by researchers at the Brady Urological Institute at Johns Hopkins, who analyzed survival statistics up to 15 years.

(Embargo expired on 31-Aug-2015 at 16:00 ET)

Journal of Clinical Oncology

– Johns Hopkins Medicine

Mayo Researchers Examine Risk Factors and Patient Outcomes Associated with Colorectal Cancer Operations, Identify Benchmarks

In the August issue of the Journal of Gastrointestinal Surgery, Mayo Clinic researchers provided a detailed comparison of patient outcomes associated with synchronous and sequential colorectal and liver resections in patients with stage IV colorectal cancer, identifying some benchmarks for surgical practice.

Journal of Gastrointestinal Surgery

– Mayo Clinic

Time-Lapse Analysis Offers New Look at How Cells Repair DNA Damage

Time-lapse imaging can make complicated processes easier to grasp. Berkeley Lab scientists are using a similar approach to study how cells repair DNA damage. Microscopy images are acquired about every thirty minutes over a span of up to two days, and the resulting sequence of images shows ever-changing hotspots inside cells where DNA is under repair.

 • Image(s) embedded • 


– Lawrence Berkeley National Laboratory

Prostate Health: What You Need to Know

September is National Prostate Health Month and expert pathologist Dr. Michael Misialek can fill you in on what you should know about prostate screening and how to talk to your doctor about next steps and treatment.

 • Image(s) embedded • 
Expert(s) available

– College of American Pathologists (CAP)

Moffitt Cancer Center Researchers Make Important Steps toward Developing a Blood Test to Catch Pancreatic Cancer Early

Pancreatic cancer is the fourth most common cause of cancer-related death in the United States and has a 5-year survival rate of only 6 percent, which is the lowest rate of all types of cancer according to the American Cancer Society.  This low survival rate is partially attributed to the difficulty in detecting pancreatic cancer at an early stage.

Cancer Prevention Research, Aug-2015

– Moffitt Cancer Center

Researchers Thwart Cancer Cells By Triggering ‘Virus Alert’

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system “virus alert” that may one day boost cancer patients’ response to immunotherapy drugs. An increasingly promising focus of cancer research, the drugs are designed to disarm cancer cells’ ability to avoid detection and destruction by the immune system.

(Embargo expired on 27-Aug-2015 at 12:05 ET)

Cell; CA058184; F32CA183214; BC031272-SBB

– Johns Hopkins Medicine

Mammary Gland Is Shaped by Adaptive Immune System During Development

In experiments with mouse tissue, UC San Francisco researchers have discovered that the adaptive immune system, generally associated with fighting infections, plays an active role in guiding the normal development of mammary glands, the only organs--in female humans as well as mice--that develop predominately after birth, beginning at puberty.

(Embargo expired on 27-Aug-2015 at 12:00 ET)

Developmental Cell

– University of California, San Francisco (UCSF)

Researchers Mimic Viral Infection in Colon Cancer Stem Cells

Researchers targeting colorectal cancer stem cells – the root cause of disease, resistance to treatment and relapse – have discovered a mechanism to mimic a virus and potentially trigger an immune response to fight the cancer like an infection.

 • Image(s) embedded •  (Embargo expired on 27-Aug-2015 at 12:00 ET)

– University Health Network (UHN)

Retinoids May Increase Effectiveness of Targeted Therapies Against High-Risk Leukemia

Scientists led by St. Jude Children’s Research Hospital have identified how mutations in the IKZF1 gene contribute to a high-risk leukemia subtype and drugs that may enhance the effectiveness of targeted therapy

 • Image(s) embedded • 

CA021765, CA23944, CA21115, CA114737

– St. Jude Children's Research Hospital

Breast Cancer Risk Score Impacts Use of Chemotherapy

A genetic test that helps predict whether some women’s breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine. The study found that low-risk patients who had the test appeared to opt for more treatment, and high-risk patients who were tested got less.

JAMA Oncology; K99HS022189

– Duke Medicine

Scientists Identify Possible Key in Virus, Cancer Research

— Florida State University researchers have taken a big step forward in the fight against cancer with a discovery that could open up the door for new research and treatment options. Fanxiu Zhu, the FSU Margaret and Mary Pfeiffer Endowed Professor for Cancer Research, and his team uncovered a viral protein in the cell that inhibits the major DNA sensor and thus the body’s response to viral infection, suggesting that this cellular pathway could be manipulated to help a person fight infection, cancer or autoimmune diseases.

Cell Host and Microbe

– Florida State University

Ovarian Cancer Survival Influenced by History of Oral Contraceptive Use

A history of oral contraceptive use and having at least one child increased longevity by nearly three years in patients diagnosed with ovarian cancer, according to a Roswell Park Cancer Institute (RPCI) study recently published online ahead of print in the International Journal of Gynecological Cancer.

International Journal of Gynecological Cancer

– Roswell Park Cancer Institute

Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report.

 • Image(s) embedded • 

New England Journal of Medicine

– Dana-Farber Cancer Institute

An Ounce of Prevention: Research Advances on ‘Scourge’ of Transplant Wards

The fungus Cryptococcus causes meningitis, a brain disease that kills about 1 million people each year. It’s difficult to treat because fungi are genetically quite similar to humans, so compounds that affect fungi tend to have toxic side effects for patients. Now, researchers at the University of Wisconsin-Madison have identified 18 proteins that play a role in spore formation and germination. The findings raises the possibility of preventing the disease by blocking the spores’ germination.

 • Image(s) embedded • 

PLOS Genetics, Aug 27-2015

– University of Wisconsin-Madison

Survivors of Childhood Cancer Have High-Risk of Recurrent Stroke

A new study from the UC San Francisco Pediatric Brain Center shows that childhood cancer survivors suffering one stroke have double the risk of suffering a second stroke, when compared with non-cancer stroke survivors.

 • Image(s) embedded •  (Embargo expired on 26-Aug-2015 at 16:00 ET)


– University of California, San Francisco (UCSF)

Study by Penn Nursing’s Bart De Jonghe May Lead to More Effective Treatment of Chemotherapy Side Effects

Bart C. De Jonghe, Ph.D., Assistant Professor of Nursing and senior author of a new study published in the highly regarded Journal of Neuroscience, has advanced our understanding of how chemotherapy causes side effects. "It is our hope that this knowledge can be used to inform future research with the goal of further limiting, or even altogether preventing, common chemotherapy side effects in cancer patients,” Dr. De Jonghe explains.

Journal of Neuroscience, Aug-2015; NIH-DK21397; NIH-NS08463

– University of Pennsylvania School of Nursing

High Use of Alternative Medicine in Senior Oncology Patients

Many seniors with cancer are also using complementary or alternative medicines that could interfere with their cancer treatment.

Journal of Geriatric Oncology

– Thomas Jefferson University

Top Stories 26 August 2015

Click to view today's top stories

– Newswise Trends

Stiffer Breast Tissue in Obese Women Promotes Tumors

Women who are obese have a higher risk and a worse prognosis for breast cancer, but the reasons why remain unclear. A Cornell study published this month in Science Translational Medicine explains how obesity changes the consistency of breast tissue in ways that are similar to tumors, thereby promoting disease.

 • Image(s) embedded • 

Science Translational Medicine

– Cornell University

The Medical Minute: When Cancer Makes Its Way to the Brain

Only half of brain cancers actually start in the brain. The rest – as in the case of former president Jimmy Carter – are metastatic tumors from cancer that originated elsewhere in the body.

– Penn State Milton S. Hershey Medical Center

NCCN Publishes New Patient Education Resources for Kidney Cancer

NCCN has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ for Kidney Cancer, the newest addition to the library of NCCN Guidelines for Patients.

– National Comprehensive Cancer Network® (NCCN®)


Wistar Institute-Spark Therapeutics, Inc. Announce Research Collaboration to Study Human Immune Responses to Liver-Directed Gene Therapy Vectors

The Wistar Institute, an international leader in biomedical research in cancer, immunology and vaccines, and Spark Therapeutics, a gene therapy leader seeking to develop one-time, life-altering treatments for debilitating genetic diseases, announced today a collaboration designed to improve the durability of gene therapy treatments targeting the liver by advancing new ways to manage the immune response to treatment.

– Wistar Institute

$2 Million Gift to Spur Research into Brain Tumors at Children’s Hospital Los Angeles

A life-changing event for a Los Angeles family has resulted in their funding an endowment to support The Kort Family Foundation Brain and Spinal Cord Tumor Research Program in the Division of Neurosurgery at Children’s Hospital Los Angeles.

 • Image(s) embedded • 

– Childrens Hospital Los Angeles

Repurposing Aspirin and a Diabetes Drug for Prostate Cancer in Obese Men

Rutgers Cancer Institute of New Jersey researcher XiangLin Tan, MD, PhD, has been awarded an $852,705 grant from the National Cancer Institute to explore the use of aspirin and a diabetes drug for prostate cancer prevention and control. Dr. Tan will examine the insulin-lowering effects of metformin and the anti-inflammatory properties of aspirin to see if the combination will prevent or delay the progression of prostate cancer, especially in obese men.

 • Image(s) embedded • 


– Rutgers Cancer Institute of New Jersey

Yale Cancer Center Receives $11 Million From National Cancer Institute for Lung Cancer Research

Armed with an $11 million grant from the National Cancer Institute (NCI), Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will launch a new research program in non-small cell lung cancer, one of the world’s most prevalent and lethal forms of cancer.

 • Image(s) embedded • 

– Yale Cancer Center

Seven Physician-Researchers Awarded a Total of $675,000 in Grants for Radiation Oncology Research

The American Society for Radiation Oncology (ASTRO) has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. Together, the seven funding grants, including ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Award and the ASTRO/Radiation Oncology Institute (ROI) Comparative Effectiveness Research Award, will support studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology. Recipients will be recognized at ASTRO’s 57th Annual Meeting, October 18-21, 2015, at the Henry B. González Convention Center in San Antonio, Texas.

– American Society for Radiation Oncology (ASTRO)

NEW! My Reading List

Save your favorite channels and articles to your reading list

Coming soon:
- My Sources
- My Sections





subscribe/unsubscribe :: edit my preferences
© 2015 Newswise, Inc. All Rights Reserved. | 215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417 | Contact Us